Case Report {#S1}
===========

A 73-year old Caucasian woman received docetaxel and cyclophosphamide chemotherapy for treatment of poorly differentiated infiltrating ductal carcinoma of the breast. Past medical history was significant for osteoporosis, hypothyroidism, and CREST syndrome for 20 to 30 years. Medications included esomeprazole, zoledronate, calcium with vitamin D, levothyroxine, fish oil, aspirin, and a multivitamin. Prior to initiation of docetaxel, she exhibited physical changes consistent with longstanding CREST syndrome, including sclerodactyly, firm subcutaneous nodules consistent with calcinosis cutis, teleangiectasias, and gastroesophageal reflux without overt esophageal dysmotility. On review of systems, she cited a history of infrequent dyspneic episodes. During therapy with docetaxel, she noticed significant swelling of her legs. Three months after completion of her chemotherapy regimen, she presented with firm, erythematous, burning plaques of her lower legs ([Figure 1](#F1){ref-type="fig"}). Additionally, she noticed worsening of her gastroesophageal reflux symptoms. Fluticasone propionate lotion was applied to the legs twice daily for 18 days without benefit. Six months after completion of her chemotherapy, she noticed a slight decrease in pain and stiffness of her legs without any other specific treatment.

Figure 1Firm, indurated, slightly erythematous plaques on bilateral lower legs.

Discussion {#S2}
==========

Scleroderma is a disease characterized by cutaneous and sometimes visceral sclerosis, vasculopathy, and the presence of autoantibodies. Localized cutaneous sclerosis is commonly termed morphea.^[@R1]^ Systemic sclerosis (SSc) may be categorized into diffuse cutaneous systemic sclerosis (dSSc) and limited cutaneous systemic sclerosis (lSSc). Diffuse cutaneous SSc is characterized by truncal and acral skin involvement, early visceral disease, and a poorer prognosis. Alternatively, limited cutaneous SSc is limited to acral cutaneous involvement of the hands, face, feet, and forearms with occasional late visceral (predominately pulmonary) involvement.^[@R1]^ CREST syndrome represents a form of lSSc and is manifested by calcinosis cutis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasias.^[@R2]^

The development of cutaneous sclerosis is typically preceded by tissue inflammation, endothelial cell activation, and edema.^[@R3]^ Histopathological changes include dermal thickening with immense collagen accumulation and resulting epidermal atrophy, flattening of rete pegs, and obliteration of hair follicles and sebaceous and sweat glands.^[@R2]^ Inflammatory cells commonly aggregate at the dermal-adipose junction, particularly in early lesions.^[@R4]^ Cytokines produced by these inflammatory cells (transforming growth factor-β,^2^ tumor necrosis factor-α (TNF- α),^[@R5],[@R6]^ interferon gamma (IFN-γ),^[@R6]^ and interleukin-6 (IL-6)^[@R7]^) are all present at high levels in the serum of patients with scleroderma, and are thought to play a central role in the pathogenesis of the disease.^[@R8]^

Several studies have demonstrated an increased incidence of breast and lung cancers in patients with pre-existing SSc. Because the cases studied have typically shown a close temporal relationship between the onset of SSc and breast cancer, a number of theories have been proposed to illuminate a pathophysiological link between the two. One theory implicates the aforementioned inflammatory cytokines as promoters of breast and lung cancers. Also, increased endothelial cell activation seen in SSc may stimulate tumor development by elevating the levels of various growth factors. Others have investigated SSc as a possible paraneoplastic syndrome in these cases. Perhaps the most widely accepted theory is that SSc is often the result of the cancer treatment itself.^[@R9]^

A variety of chemical agents, including rapeseed oil, organic solvents, herbicides, silica, cocaine, bleomycin, penicillamine, L-tryptophan, pentazocine, ethosuximide,^[@R10]^ and the taxane family of chemotherapeutic medications^[@R11]^ have been associated with scleroderma or scleroderma-like changes of the skin.

The taxanes, which include docetaxel and paclitaxel, exert their antineoplastic effects by stabilizing microtubules thus halting mitosis and by inhibiting Bcl-2 to allow apoptosis.^[@R12]^ These medicines are widely used in the treatment of breast, lung, and ovarian carcinomas.^[@R13]^ Established toxicities include peripheral edema, neutropenia, and neuropathy.^[@R11]^ In addition to scleroderma-like changes, cutaneous reactions of the taxanes include acral erythema, pustular eruption, bullous fixed drug eruption, erythema multiforme, onycholysis, erythrodyesthesia, and alopecia.^[@R11],[@R14]^

There is a well-established association between the taxanes and scleroderma-like skin changes. Edema characteristically precedes the development of generalized morphea by a few months, and the sclerosis develops most prominently on the lower legs, sparing the hands and feet.^[@R11]^ The taxanes cause an increase in the expression of several of the same inflammatory cytokines that are naturally increased in patients with scleroderma, including TNF-α, IL-2, IL-6, and INF-γ.^[@R2],[@R11]^ This immunological *milieu* likely contributes to both the taxanes' therapeutic efficacy and the development of skin sclerosis.

Several cases of taxane-induced scleroderma have displayed dramatic improvement with simple withdrawal of chemotherapy.^[@R14],[@R15]^ Alternatively, it may be treated with systemic steroids and/or d-penicillamine.^[@R11],[@R16]^ Ironically, pencillamine has also been implicated as a cause of cutaneous sclerosis.^[@R10]^

We present this case because of our patient's distinguishing feature of pre-existing CREST syndrome. Patients with a history of scleroderma and subsequent or concurrent neoplasia may be immunologically predisposed to the development of drug-induced morphea. We propose that this population should be given taxane chemotherapy with caution in order to decrease the incidence of this rare, but potentially debilitating, side effect.
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